Apellis Pharmaceuticals I... (APLS)
28.38
-0.01 (-0.04%)
At close: Feb 20, 2025, 3:59 PM
28.35
-0.11%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 27.5 |
| Market Cap | 3.53B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.03 |
| PE Ratio (ttm) | -13.98 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 28.97 |
| Volume | 1,166,891 |
| Avg. Volume (20D) | 2,202,296 |
| Open | 28.54 |
| Previous Close | 28.39 |
| Day's Range | 27.92 - 28.94 |
| 52-Week Range | 24.34 - 71.90 |
| Beta | undefined |
About APLS
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal ...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 9, 2017
Employees 702
Stock Exchange NASDAQ
Ticker Symbol APLS
Website https://www.apellis.com
Analyst Forecast
According to 18 analyst ratings, the average rating for APLS stock is "Buy." The 12-month stock price forecast is $41, which is an increase of 44.47% from the latest price.
Buy 55.56%
Hold 44.44%
Sell 0.00%
Next Earnings Release
Apellis Pharmaceuticals Inc. is scheduled to release its earnings on Feb 28, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+4.19%
Apellis Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
3 months ago
-1.68%
Apellis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results.
